- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03043313
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body.
In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Other
-
Brussels, Other, Belgium, 1200
- Cliniques Universitaires Saint Luc
-
Edegem, Other, Belgium, 2650
- Universitair Ziekenhuis Antwerpen
-
Leuven, Other, Belgium, 3000
- UZ Leuven campus Gasthuisberg
-
-
-
-
Other
-
Besancon, Other, France, 25030
- Hospitalier Jean Minjoz
-
Dijon, Other, France, 21000
- Center Georges Francois Leclerc
-
Levallois-Perret, Other, France, 92300
- Hopital Franco-Britannique - Fondation Cognacq-Jay
-
Lyon, Other, France, 69373
- Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes
-
Paris, Other, France, 75012
- Hopital Saint-Antoine
-
-
-
-
Other
-
Milan, Other, Italy, 20141
- Instituto Europeo di Oncologia
-
Milan, Other, Italy, 20162
- Niguarda Ca' Granda Hospital
-
Pisa, Other, Italy, 56126
- Azienda Ospedaliero-Universitaria Pisana - Ospedale S. Chiara
-
-
-
-
Other
-
Barcelona, Other, Spain, 08035
- Hospital Universitario Vall d'Hebron
-
L'Hospitalet de Llobregat, Other, Spain, 08907
- Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
-
Madrid, Other, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Valencia, Other, Spain, 46010
- Hospital Clinico Universitario de Valencia
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- University of Alabama at Birmingham
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic Arizona
-
-
California
-
Long Beach, California, United States, 90813
- Pacific Shores Medical Group
-
Los Angeles, California, United States, 90048
- Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute
-
Los Angeles, California, United States, 90033
- Keck Medical Center / University of Southern California
-
Palo Alto, California, United States, 94304
- Stanford University School of Medicine
-
Santa Rosa, California, United States, 95403
- Saint Joseph Heritage Medical Group
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Rocky Mountain Cancer Centers - Aurora
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Lombardi Cancer Center / Georgetown University Medical Center
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Florida Cancer Specialists - South Region
-
Saint Petersburg, Florida, United States, 33705
- Florida Cancer Specialists - North Region
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute / Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60637-1470
- University of Chicago Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Simon Cancer Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- University of Kansas Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute / Wayne State University
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Rochester
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Comprehensive Cancer Centers of Nevada
-
-
New York
-
Buffalo, New York, United States, 14203
- Roswell Park Cancer Institute
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University / University Hospitals Cleveland Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Oregon Health and Science University
-
Portland, Oregon, United States, 97227
- Northwest Cancer Specialists, P.C.
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute
-
-
Texas
-
Beaumont, Texas, United States, 77702-1449
- Texas Oncology - Beaumont
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Sammons Cancer Center
-
Lubbock, Texas, United States, 79410
- Joe Arrington Cancer Research and Treatment Center
-
McAllen, Texas, United States, 78503
- Texas Oncology - McAllen
-
San Antonio, Texas, United States, 78240
- Texas Oncology - San Antonio Medical Center
-
Tyler, Texas, United States, 75702
- Texas Oncology - Tyler
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Washington
-
Everett, Washington, United States, 98201
- Providence Regional Medical Center Everett
-
Seattle, Washington, United States, 98109-1023
- Seattle Cancer Care Alliance / University of Washington
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Aurora Research Institute Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Histologically and/or cytologically documented adenocarcinoma of the colon or rectum that is metastatic and/or unresectable
- Unless contraindicated, participants must have received and failed regimens containing the following agents: fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab, or ziv-aflibercept), and an anti-PD-(L)1 therapy (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins or is MSI-High.
- Have progression of unresectable or metastatic CRC after the last systemic therapy, or be intolerant of last systemic therapy
- Have RAS wild-type in primary or metastatic tumor tissue, based on expanded RAS testing
- Willing and able to provide the most recently available tissue blocks obtained prior to treatment initiation. If archival tissue is not available, then a newly-obtained baseline biopsy of an accessible tumor
Have confirmed HER2-positive mCRC, as defined by having tumor tissue tested at a Clinical Laboratory Improvement Act (CLIA)-certified or International Organization for Standardization (ISO)-accredited laboratory, meeting at least one of the following criteria:
- HER2+ overexpression (3+ immunohistochemistry [IHC]) by an FDA-approved or Conformité Européene (CE)-marked HER2 ICH test
- HER2 2+ IHC is eligible if the tumor is amplified by an FDA-approved or CE-marked HER2 in situ hybridization assay (FISH or chromogenic in situ hybridization [CISH]))
- HER2 (ERBB2) amplification by CLIA-certified or ISO-accredited next generation sequencing (NGS) sequencing assay
- Have radiographically measurable disease assessable by RECIST 1.1, with at least one site of disease that is measurable and that has not been previously irradiated; or, if the participant has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
- Life expectancy greater than 3 months
- Have adequate hematological, hepatic, renal, coagulation, and cardiac function
Exclusion Criteria
- Previous treatment with anti-HER2 targeting therapy
- Previous treatment with any systemic anticancer therapy, non-central nervous system radiation, or experimental agent within 3 weeks of first dose of study treatment
Toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:
- Alopecia and neuropathy, which must have resolved to ≤ Grade 2
- Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence, and must have resolved completely
- Anemia, which must have resolved to ≤ Grade 2
- Decreased ANC, which must have resolved to ≤ Grade 2
- Have clinically significant cardiopulmonary disease
- Have known myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac surgery within 6 months prior to first dose of study treatment
- Major surgical procedure, open biopsy, or significant traumatic injury ≤28 days prior to enrollment (≤56 days for hepatectomy, open thoracotomy, or major neurosurgery) or anticipation of need for major surgical procedure during the study
- Serious, non-healing wound, ulcer, or bone fracture
- Known to be positive for hepatitis B by surface antigen expression
Known to have active hepatitis C infection
- Exception for participants with a documented sustained virologic response of 12 weeks
- Known to be positive for human immunodeficiency virus (HIV)
- Subjects who are pregnant, breastfeeding, or planning a pregnancy
- Inability to swallow pills or any significant gastrointestinal disease which would preclude the adequate oral absorption of medications
- Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a strong CYP2C8 or CYP3A4 inducer within 5 days prior to first dose of study treatment
History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.
- Exceptions are malignancies with a negligible risk of metastasis or death
Subjects with known active CNS metastasis
- Irradiated or resected lesions are permitted, provided the lesions are fully treated and inactive, subject is asymptomatic, and no steroids have been administered for at least 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A: Tucatinib + Trastuzumab
Non-randomized cohort.
Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
|
Given intravenously (into the vein; IV)
Other Names:
Given orally
Other Names:
|
Experimental: Cohort B: Tucatinib + Trastuzumab
Randomized cohort.
Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
|
Given intravenously (into the vein; IV)
Other Names:
Given orally
Other Names:
|
Experimental: Cohort C: Tucatinib Monotherapy
Randomized cohort.
Participants take tucatinib twice per orally every day.
Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
|
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Objective Response Rate (cORR) Per RECIST 1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B
Time Frame: Up to 46.6 months
|
cORR is defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
|
Up to 46.6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR by 12 Weeks of Treatment Per RECIST 1.1 According to BICR Assessment
Time Frame: Up to 3 months
|
ORR per BICR by 12 Weeks is defined as the percentage of participants with CR or PR by 12 weeks of treatment, and before time of crossover (Cohort C), whichever comes earlier.
|
Up to 3 months
|
Duration of Response (DOR) Per RECIST 1.1 According to BICR Assessment
Time Frame: Up to 44.7 months
|
DOR is defined as the time from the first objective response (CR or PR that is subsequently confirmed) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first.
|
Up to 44.7 months
|
Progression-Free Survival (PFS) Per RECIST 1.1 According to BICR Assessment for Pooled Cohorts A+B
Time Frame: Up to 46.6 months
|
PFS is defined as the time from start of study treatment (Cohort A) or date of randomization (Cohort B) to documented disease progression (as determined by BICR per RECIST 1.1) or death from any cause, whichever occurs first.
|
Up to 46.6 months
|
Overall Survival (OS) in Pooled Cohorts A+B
Time Frame: Up to 53 months
|
OS is defined as the time from start of study treatment (Cohort A) or randomization (Cohort B) to date of death due to any cause.
|
Up to 53 months
|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 49.3 months
|
An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment (tucatinib or trastuzumab) and up through 30 days after the last dose of study treatment (tucatinib or trastuzumab).
|
Up to 49.3 months
|
Number of Participants With AEs Resulting in Dose Modification
Time Frame: Up to 49.3 months
|
Dose modification included dose reduction and dose withheld by investigator due to AEs.
Dose holds were defined as any instances where planned administration of the study drug was temporarily withheld or interrupted at the direction of the treating physician.
Dose reductions of trastuzumab were not allowed; if trastuzumab could not be restarted after being held for a TEAE, it was discontinued.
|
Up to 49.3 months
|
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology)
Time Frame: Up to 49.3 months
|
Treatment emergent laboratory abnormalities are defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.
NCI CTCAE v5.0 is used for creatinine increased.
NCI CTCAE v4.03 is used for the other lab parameters.
|
Up to 49.3 months
|
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Chemistry)
Time Frame: Up to 49.3 months
|
Treatment emergent laboratory abnormalities are defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.
NCI CTCAE v5.0 is used for creatinine increased.
NCI CTCAE v4.03 is used for the other lab parameters.
|
Up to 49.3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: John H Strickler, Academic and Community Cancer Research United
- Study Director: Jorge Ramos, DO, Seagen Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Trastuzumab
- Tucatinib
Other Study ID Numbers
- SGNTUC-017
- P30CA015083 (U.S. NIH Grant/Contract)
- NCI-2017-01107 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- ACCRU-GI-1617 (Other Identifier: Academic and Community Cancer Research United)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Adenocarcinoma
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal CarcinomaUnited States
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Not yet recruitingMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8United States
-
Centre Hospitalier Universitaire DijonCompletedMetastatic Colorectal AdenocarcinomaFrance
-
University of Campania "Luigi Vanvitelli"Active, not recruitingMetastatic Colorectal AdenocarcinomaItaly
-
Memorial Sloan Kettering Cancer CenterBayer; State University of New York - Downstate Medical Center; Queens Cancer...Active, not recruitingMetastatic Colorectal AdenocarcinomaUnited States
-
Hunan Cancer HospitalCompletedMetastatic Colorectal AdenocarcinomaChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
Clinical Trials on Trastuzumab
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingBreast Ductal Carcinoma In SituUnited States, Canada, Puerto Rico, Korea, Republic of
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
Spanish Breast Cancer Research GroupCompleted
-
Fudan UniversityHoffmann-La RocheUnknown
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | NeratiniChina
-
Orano Med LLCCompletedStomach Neoplasms | Breast Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Peritoneal NeoplasmsUnited States
-
Samsung Bioepis Co., Ltd.TerminatedBreast NeoplasmsUkraine, Romania, Russian Federation, France, Bulgaria, Czechia, Poland
-
University Medical Center GroningenCompleted
-
Fudan UniversityCompleted
-
National Cancer Institute (NCI)Active, not recruitingMale Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7United States, Puerto Rico